Oral GLP‑1 approved

Weight-loss drugs work by copying a gut hormone that slows digestion and dampens hunger. On December 22, 2025, the Food and Drug Administration approved Wegovy tablets, making semaglutide the first oral glucagon-like peptide-1 pill cleared in the United States for chronic weight management. (fda.gov) The approval covers adults with obesity, and adults who are overweight with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. The label also says the tablets can be used to reduce major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. (fda.gov) The decision rested on the Phase 3 OASIS 4 trial, a 64-week study of 307 adults without diabetes. Participants taking oral semaglutide 25 milligrams lost 13.6% of body weight on average in the main analysis, versus 2.2% with placebo. (nejm.org) In a second analysis that estimated results if everyone had stayed on treatment, average weight loss reached 16.6% with the pill and 2.7% with placebo. More than one-third of adherent patients on semaglutide lost at least 20% of body weight, compared with 2.9% on placebo. (nejm.org) A pill changes the mechanics of treatment as much as the chemistry. Weekly injections helped turn semaglutide into a major obesity drug, but the tablet gives doctors a version for patients who avoid needles or want a daily oral option. (ajmc.com) The tradeoff is convenience of form versus convenience of use. The Food and Drug Administration label says patients must take one tablet every morning on an empty stomach with up to 4 ounces of water and wait 30 minutes before eating, drinking anything else, or taking other oral medicines. (fda.gov) The safety profile looked similar to the injectable class. In OASIS 4, the most common adverse events were gastrointestinal, and serious adverse events were reported less often with oral semaglutide than with placebo, 3.9% versus 8.8%. (appliedclinicaltrialsonline.com) Researchers also reported changes beyond the scale. At ObesityWeek 2025, Novo Nordisk said 71.1% of participants with prediabetes on oral semaglutide returned to normal blood sugar by week 64, versus 33.3% on placebo, and larger weight loss tracked with bigger drops in blood pressure and triglycerides. (novonordisk.mediaroom.com) Novo Nordisk said on December 22, 2025, that a 1.5 milligram starting dose would reach the United States market in early January 2026 and listed a $149-per-month self-pay price with savings offers. The label carries the same boxed warning used across semaglutide products about thyroid C-cell tumors seen in rodents, and it says the drug is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. (prnewswire.com, fda.gov) The result is a new front in the obesity-drug market: the same semaglutide molecule that made Wegovy a weekly injection is now also a daily tablet. For patients and prescribers, the question is no longer whether a glucagon-like peptide-1 can come as a pill, but who will use one and stick with its morning routine. (fda.gov, nejm.org)